arrow-circle-full-right arrow-circle-full-up arrow-circle-up arrow-down arrow-right calendar calendar-done facebook flickr home linkedin login pin reload search share signin star twitter video video youtube nav star-plus info signout double-arrow arrow-up checked
Healthcare & Life Sciences

FT Pharma Pricing and Value Summit 2020

Forging the future of market access

New York |
Speakers include:
Hannah Kuchler

Hannah Kuchler

Financial Times

Sarah Neville

Sarah Neville

Financial Times

Alex Azar

Alex Azar

United States

Overview

The American pharmaceutical pricing and market access landscape is rapidly evolving. Companies are introducing new products like gene therapies that require alternative pricing models. Payers are seeking to increase their negotiating power through joint healthcare ventures. Regulators are approving products based on real-world evidence. Meanwhile, presidential candidates are offering very different healthcare policy visions with huge implications for drug pricing. 

The FT Pharma Pricing and Value Summit will envision the future of market access from different perspectives with a special focus on innovation and collaboration. How can pharma better articulate value to payers and patients? What early steps can be taken to unlock commercial potential in product pipelines? Should the US have an official ICER-like body? You attend - you decide! 

fallback
fallback Add to my Calendar 09/29/2020 08:00:0009/29/2020 16:01:00trueFT Pharma Pricing and Value Summit 2020The American pharmaceutical pricing and market access landscape is rapidly evolving. Companies are introducing new products like gene therapies that require alternative pricing models. Payers are seeking to increase their negotiating power through joint healthcare ventures. Regulators are approving products based on real-world evidence. Meanwhile, presidential candidates are offering very different healthcare policy visions with huge implications for drug pricing. The FT Pharma Pricing and Value Summit will envision the future of market access from different perspectives with a special focus on innovation and collaboration. How can pharma better articulate value to payers and patients? What early steps can be taken to unlock commercial potential in product pipelines? Should the US have an official ICER-like body? You attend - you decide! FT-Pharma-Pricing-and-Value-Summit-2020b4b1615a72fddb4a9aef205f43bb7dbaMM/DD/YYYY

Brochure downloads

Pre-event insights into the pharma industry

Download now

Event Brochure

To download the event brochure please fill in the form below. All fields are required

Please complete all the highlighted fields

Form submission failed. Please retry.

For more information about how we use your data please refer to our privacy and cookie policies.

Invites and offers from the FT

Receive exclusive personalised events invitations, carefully-curated offers, future speaking engagements and promotions from Financial Times Live

Thank you for submitting your details. Please download the event brochure.

2019 Event Highlights

Flicker 2019

Click here for images

More

Testimonials

"Excellent level of debate"

Mariângela Simão, Assistant Director-General, Access to Medicines, Vaccines and Pharmaceuticals, WHO

"Helps us stay in front of the trends and challenges impacting healthcare today"

Rick Suarez, Senior Vice President, US Market Access, AstraZeneca

More

Agenda - 29th Sep

  • 8:00am
    Registration and Breakfast
  • 9:00am
    Opening Remarks
  • 9:05am
    Presidential Visions for US Healthcare and Drug Pricing Policy

    Candidates for the Presidential election are offering two very different visions for healthcare in the US. The current administration is relatively aligned with the status quo but what is the challenger promising, is it deliverable and what would it mean for drug prices?

  • 9:35am
    Panel: The Pricing and Market Access Policy Landscape
    • What are the prospects for an ICER-like body to have a more formal role in drug pricing?
    • Is Medicare for All really on the table?
    • What reforms could support increased access to biosimilars and orphan drugs?
    • What can be done to stop patent gaming?
    • How could the FDA’s role in relation to market access evolve?
    • How are political and regulatory pricing pressures changing operating models?
  • 10:20am
    Unlocking Value in Product Pipelines

    In an industry where products take years to develop, acting early to understand market potential is critical to long-term success. So, what can decision-makers do from the outset to assess value, manage risks and accelerate progress towards successful commercialization?

  • 10:50am
    Refreshments
  • 11:15am
    Enabling Global Access to Advanced Therapies

    Negotiating drug prices in countries with single payer healthcare systems is a whole different ball game. As new products like gene therapies come to market, what will the path to patients look like in Europe and other regions?

  • 11:45am
    Empowering Payers through Joint Healthcare Ventures

    As payers seek new ways to shift the balance of power towards them in pricing negotiations, several major joint healthcare ventures have been formed. But how workable are they and where is the evidence of progress?

  • 12:15pm
    Panel: Building Value-Based Pricing Models
    • In what ways do stakeholders differ in how they measure value?
    • Is value-based pricing viable without an ICER-like entity to independently determine value?
    • How can the value of a product be measured against an alternative such as a transplant?
    • How are pricing models for advanced therapies evolving?
    • What are the prospects for international reference pricing in value-based agreements?
    • Is there a role for blockchain in measuring value and outcomes?
  • 1:00pm
    Networking Lunch
  • 2:00pm
    Debate: Should the US have an Official ICER-like Body?

    Different opinions exist on the legitimacy of using ICER as a reference for health technology assessment. If an organization like that was given official status – as is the case in many countries – it could be a game-changer for drug pricing in the US.

  • 2:40pm
    Panel: Strengthening Stakeholder Relations
    • How can pharma better articulate value to payers and patients?
    • In what ways could stakeholder relations become less transactional and more collaborative?
    • How can patient advocacy groups better support access to new expensive drugs?
    • What are the pros and cons of making drug pricing more transparent?
    • What barriers could be removed to make it easier for pharma to engage with other stakeholders?
  • 3:25pm
    Maximizing the Potential of Real-World Evidence

    The use of real-world evidence to prove value to payers is a growing trend and is strongly aligned with the shift towards outcomes-based contracts. As technology creates new opportunities to collect and analyze data, how can companies make the most of it and what barriers could they face?

  • 3:55pm
    Closing Remarks
  • 4:00pm
    Drinks Reception

Chair and Moderators (2)

Hannah Kuchler

Hannah Kuchler

US Pharma and Biotech Correspondent
Financial Times

Hannah Kuchler is US Pharma and Biotech Correspondent for the Financial Times, with a particular focus on how technology is transforming healthcare. For five years, Ms Kuchler served as FT’s San Francisco Correspondent where she covered Silicon Valley and technology with a focus on social media and cyber security. Ms Kuchler was previously a London-based UK news reporter for the FT, covering British politics and general UK news. Prior to this, she worked on the FT’s newsdesk, as Asia Correspondent for FT Tilt in Hong Kong, and covered US markets in New York.  Before joining the FT in 2009, Ms Kuchler was the Editor of The Oxford Student and won the Guardian’s Student Reporter of the Year award in 2008. She holds a Bachelor’s degree in Modern History from Balliol College, Oxford.

Sarah Neville

Sarah Neville

Global Pharmaceuticals Editor
Financial Times

Sarah Neville is Global Pharmaceuticals Editor of the Financial Times, a position she has held since 2016. She joined the Financial Times in 2001 and has held a series of senior roles, including Weekend News Editor, Analysis Editor, UK News Editor and Public Policy Editor. She began her career on local and regional newspapers, eventually becoming Political Editor of the Yorkshire Post. In 1995 she was awarded the Laurence Stern Fellowship on the Washington Post. 

Previous Speakers (6)

Alex Azar

Alex Azar

Secretary of Health and Human Services
United States

Alex M. Azar II was sworn in as the Secretary of Health and Human Services on Jan. 29, 2018. Azar has spent his career working in both the public and private sectors, as an attorney and in senior leadership roles focused on advancing healthcare reform, research and innovation.

From 2001 to 2007, Azar served at the U.S. Department of Health and Human Services – first as its General Counsel (2001–2005) and then as Deputy Secretary. During his time as Deputy Secretary, Azar was involved in improving the department’s operations; advancing its emergency preparedness and response capabilities as well as its global health affairs activities; and helping oversee the rollout of the Medicare Part D prescription drug program.

In 2007, Azar rejoined the private sector as senior vice president for corporate affairs and communications at Eli Lilly and Co. From 2012 to 2017, he served as president of Lilly USA LLC, the company’s largest affiliate.

Azar clerked for U.S. Supreme Court Justice Antonin Scalia prior to practicing law for several years.

Azar graduated summa cum laude with a bachelor’s degree in economics and government from Dartmouth College and earned his law degree from Yale University.

For the past 10 years, Azar has lived in Indiana with his wife and their two children.

Chris Leibman

Chris Leibman

Senior Vice President, Value and Access
Biogen

Chris Leibman is Senior Vice President, Value and Access at Biogen, where he leads the global value demonstration, access and pricing strategy development and execution across the Biogen portfolio. Prior to this role Chris lived in Zug, Switzerland where he led market access and pricing at Biogen for Europe and Canada. Chris joined Biogen in 2014 from Janssen Pharmaceuticals, where he served as head of Market Access and Policy: Neuroscience and led the team responsible for the development and execution of market access strategies and value evidence generation across the neuroscience franchise. Prior to this, first with Élan Pharmaceuticals and then with Janssen AI following their program acquisition, Chris led the market access launch readiness activities across the Alzheimer Immunotherapy Program in partnership with Pfizer. Chris has published and presented extensively on the benefits and costs of prescription drugs in Alzheimer’s disease, value frameworks in healthcare, and sustainable pricing in drug development. He brings two decades of diverse experiences in biopharmaceutical development, value demonstration, access, and working across multi-company alliances. Chris holds a B.S. degree in biology, from the University of Illinois at Urbana-Champaign and Doctor of Pharmacy from the University of Illinois at Chicago. Following his pharmacy degree, he completed a post-doc fellowship in health economics with GlaxoWellcome and earned a M.S. degree with focus in pharmacoeconomics and health policy from the Ohio State University.

Sarah Emond

Sarah Emond

Executive Vice President and Chief Operating Officer
Institute for Clinical and Economic Review (ICER)

Sarah Emond leads the strategic planning and operations of the Institute for Clinical and Economic Review (ICER), a leading non-profit health policy research organisation, as Executive Vice President and Chief Operating Officer. In that role, she is responsible for overseeing ICER’s public programs, communications, operations, and finances.
Prior to joining ICER, Ms Emond spent time as a communications consultant, with six years in the corporate communications and investor relations department at a commercial-stage biopharmaceutical company, and several years with a healthcare communications firm. She began her healthcare career in clinical research at Beth Israel Deaconess Medical Center in Boston.
A graduate of the Heller School for Social Policy and Management at Brandeis University, Ms Emond holds a Master of Public Policy degree with a concentration in health policy. She also received a Bachelor’s degree in Biological Sciences from Smith College.

Doug Ingram

Doug Ingram

President and Chief Executive Officer
Sarepta Therapeutics

Douglas S. Ingram has served as Sarepta Therapeutics President, Chief Executive Officer and a member of the Board since June 2017. Prior to his appointment, from December 2015 until November 2016, he served as the Chief Executive Officer and President and a Director of Chase Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company. Prior to joining Chase Pharmaceuticals, Mr Ingram served as the President of Allergan from July 2013 until it was acquired by Actavis in early 2015. At Allergan, he also served as President, Europe, Africa and Middle East from August 2010 to June 2013, and Executive Vice President, Chief Administrative Officer, and Secretary from October 2006 to July 2010, where he led Allergan’s Global Legal Affairs, Compliance, Internal Audit and Internal Controls, Human Resources, Regulatory Affairs and Safety, and Global Corporate Affairs and Public Relations departments. Mr Ingram also served as General Counsel of Allergan from January 2001 to June 2009 and as Secretary and Chief Ethics Officer from July 2001 to July 2010. Mr Ingram received his Juris Doctor from the University of Arizona and his Bachelor of Science degree from Arizona State University. He is a board member for Relay Therapeutics.

Rick Suarez

Rick Suarez

Senior Vice President, US Market Access
AstraZeneca

Rick R. Suarez is Senior Vice President, US Market Access at AstraZeneca where he leads teams responsible for securing patient access to AstraZeneca medicines in collaboration with national and regional payers, distributors, retailers, wholesalers and Group Purchasing Organizations (GPOs).  Rick’s teams are also responsible for reimbursement support and one of the longest-standing patient assistance programs in the industry. He has nearly two decades of diverse experience in healthcare leading teams aligned to Sales, Marketing, and Market Access, including heading up the NEXIUM franchise. He holds a BS in Chemistry and Sociology from the University of N. Alabama. Rick brings unique perspective on the external environment and the move towards greater focus on value-based payment. Under his leadership, AstraZeneca has emerged as an industry leader in value-based agreements.

Seema Verma

Seema Verma

Administrator
Centers for Medicare & Medicaid Services

Seema Verma currently serves as Administrator of the Centers for Medicare & Medicaid Services (CMS), and she is only the 15th person ever confirmed to the post. She was nominated by President Trump on November 29, 2016 – the seventh nomination by the President-elect – and confirmed by the U.S. Senate on March 13, 2017. As Administrator, Ms Verma oversees a $1 trillion budget, 26% of the total federal budget, and administers healthcare programs for more than 130 million Americans every day.

A nationally recognized leader in health policy and operational design, she has guided healthcare policy in the public and private sector, working with states to build flexibility into their Medicaid programs to help them meet the diverse needs of their unique populations. 

Administrator Verma is a graduate of the University of Maryland, and holds a Master’s degree in Public Health with a concentration in health policy and management from Johns Hopkins University.

Her editorial commentaries have appeared in the Wall Street Journal, Washington Post and Health Affairs, and she also previously served as Vice President of Planning for the Health & Hospital Corporation of Marion County, Indiana and most recently before heading CMS was President and CEO of SVC, Inc.

fallback

Who will be there?

FT Live has a reputation for delivering very senior, board-level audiences to attend a wide range of world-class thought-leadership events across the globe for nearly 40 years.

The FT Pharma Pricing and Value Summit will be attended by:

  • Pharmaceutical companies
  • Pharmacy benefit managers
  • Medical device manufacturers
  • Healthcare providers and insurers
  • Patient representatives and NGOs
fallback

SPONSORSHIP OPPORTUNITIES

  • Gain access to 180 senior executives and influential stakeholders from across the US drug pricing debate;
  • Brand alignment with the FT and its unrivalled credibility;
  • Demonstrate thought leadership around the current critical issues affecting the healthcare industry;
  • Benefit from sustained international visibility through our advertising and marketing campaigns

Joe Hames

Head of Portfolio

M: +44 (0)791 329 2038

E: joe.hames@ft.com

fallback

Venue

Convene
730 Third Avenue
New York 10017

United States of America

Tel: (646) 854-7950

fallback

PRESENTED BY (1)

The Financial Times is one of the world’s leading business news organisations, recognised internationally for its authority, integrity and accuracy. The FT has a record paying readership of one million, three-quarters of which are digital subscriptions. It is part of Nikkei Inc., which provides a broad range of information, news and services for the global business community.

Global Clinical Research Partner (1)

ICON plc is a global provider of outsourced drug development and commercialisation solutions and services to pharmaceutical, biotechnology, medical device, and government and public health organisations. The company specialises in the strategic development, management and analysis of programs that support clinical development. ICON offers a full range of consulting, development and commercialisation services that help clients to accelerate the development of drugs and devices that save lives and improve quality of life.

ICON’s award-winning study execution capabilities have led to the approval of 18 of the world’s top 20 best-selling drugs.

With headquarters in Dublin, Ireland, ICON currently, operates from 98 locations in 40 countries and has approximately 14,500 employees. For further information please visit www.iconplc.com  Follow @iconplc on Twitter.

CONTACTS

Alexsandra Silva
Media Partner and Press Enquiries
Financial Times
Joe Hames
Sponsorship & Exhibitor Opportunities
Financial Times
Ciaran Larkin
Content Manager
Financial Times Live